open access
Circulating asprosin, irisin, and abdominal obesity in Chinese patients with type 2 diabetes mellitus: a case-control study
, 1, 1, 1
Affiliations- Department of Endocrinology, The Third Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, China
open access
Abstract
Introduction: Studies have suggested that serum asprosin and irisin were involved in type 2 diabetes mellitus (T2DM) and obesity. This study evaluated circulating levels of asprosin and irisin and their associations with anthropometric and metabolic parameters, especially the visceral fat area (VFA) in T2DM patients with abdominal obesity (AO).
Material and methods: In this case-control study, 131 patients with T2DM were grouped into an AO group (n = 68) and a non-AO group (NAO) (n = 63) based on their VFA. Anthropometric and metabolic parameters as well as serum asprosin and irisin levels were measured and compared between the 2 groups.
Results: Compared to the NAO group, the AO group had significantly higher serum asprosin and irisin concentrations (3.67 ± 1.76 ng/mL vs. 2.85 ± 0.90 ng/mL, p = 0.001; 154.62 ± 61.87 pg/mL vs. 130.54 ± 34.89 pg/mL, p = 0.008, respectively) and greater VFA (p < 0.001). Serum asprosin in the AO group was positively associated with weight, waist circumference (WC), hipline, body mass index, fasting blood glucose (FBG), glycated haemoglobin (HbA1c), VFA, subcutaneous fat area, and total abdominal fat area (TAFA), and the serum irisin concentration in the AO group was positively correlated with WC, waist-to-hip ratio (WHR), VFA, and TAFA and negatively correlated with FBG. Stepwise logistic regression analysis suggested that FBG and VFA were independent factors positively associated with serum asprosin, and that FBG was independently, negatively associated with serum irisin, while VFA was independently, positively associated with serum irisin.
Conclusions: Elevated serum asprosin and irisin levels in T2DM patients with AO and their correlations with other metabolic parameters suggest that both are potential therapeutic agents/targets in treating obesity and its related disorders.
Abstract
Introduction: Studies have suggested that serum asprosin and irisin were involved in type 2 diabetes mellitus (T2DM) and obesity. This study evaluated circulating levels of asprosin and irisin and their associations with anthropometric and metabolic parameters, especially the visceral fat area (VFA) in T2DM patients with abdominal obesity (AO).
Material and methods: In this case-control study, 131 patients with T2DM were grouped into an AO group (n = 68) and a non-AO group (NAO) (n = 63) based on their VFA. Anthropometric and metabolic parameters as well as serum asprosin and irisin levels were measured and compared between the 2 groups.
Results: Compared to the NAO group, the AO group had significantly higher serum asprosin and irisin concentrations (3.67 ± 1.76 ng/mL vs. 2.85 ± 0.90 ng/mL, p = 0.001; 154.62 ± 61.87 pg/mL vs. 130.54 ± 34.89 pg/mL, p = 0.008, respectively) and greater VFA (p < 0.001). Serum asprosin in the AO group was positively associated with weight, waist circumference (WC), hipline, body mass index, fasting blood glucose (FBG), glycated haemoglobin (HbA1c), VFA, subcutaneous fat area, and total abdominal fat area (TAFA), and the serum irisin concentration in the AO group was positively correlated with WC, waist-to-hip ratio (WHR), VFA, and TAFA and negatively correlated with FBG. Stepwise logistic regression analysis suggested that FBG and VFA were independent factors positively associated with serum asprosin, and that FBG was independently, negatively associated with serum irisin, while VFA was independently, positively associated with serum irisin.
Conclusions: Elevated serum asprosin and irisin levels in T2DM patients with AO and their correlations with other metabolic parameters suggest that both are potential therapeutic agents/targets in treating obesity and its related disorders.
Keywords
type 2 diabetes mellitus; abdominal obesity; asprosin; irisin; visceral fat area
About this articleTitle
Circulating asprosin, irisin, and abdominal obesity in Chinese patients with type 2 diabetes mellitus: a case-control study
Journal
Issue
Article type
Original paper
Pages
55-62
Published online
2022-12-15
Page views
3043
Article views/downloads
513
DOI
Pubmed
Bibliographic record
Endokrynol Pol 2023;74(1):55-62.
Keywords
type 2 diabetes mellitus
abdominal obesity
asprosin
irisin
visceral fat area
Authors
Guoping Hu
Wei Si
Qiang Zhang
Fang Lv
References (38)- Asakawa H, Tokunaga K, Kawakami F, et al. Relationship of leptin level with metabolic disorders and hypertension in Japanese type 2 diabetes mellitus patients. J Diabetes Complications. 2001; 15(2): 57–62.
- Cho M, Park JS, Nam J, et al. Association of abdominal obesity with atherosclerosis in type 2 diabetes mellitus (T2DM) in Korea. J Korean Med Sci. 2008; 23(5): 781–788.
- Wang Y, Ma X, Zhou M, et al. Contribution of visceral fat accumulation to carotid intima-media thickness in a Chinese population. Int J Obes (Lond). 2012; 36(9): 1203–1208.
- Omura-Ohata Y, Son C, Makino H, et al. Efficacy of visceral fat estimation by dual bioelectrical impedance analysis in detecting cardiovascular risk factors in patients with type 2 diabetes. Cardiovasc Diabetol. 2019; 18(1): 137.
- Chinese Medical Association, Chinese Medical Journals Publishing House, Chinese Society of General Practice. [2019 Guideline for primary care of obesity]. Chin J Gen Pract. 2020; 19: 95–101.
- Zhang L, Chen C, Zhou N, et al. Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clin Chim Acta. 2019; 489: 183–188.
- Goodarzi G, Setayesh L, Fadaei R, et al. Circulating levels of asprosin and its association with insulin resistance and renal function in patients with type 2 diabetes mellitus and diabetic nephropathy. Mol Biol Rep. 2021; 48(7): 5443–5450.
- Naiemian S, Naeemipour M, Zarei M, et al. Serum concentration of asprosin in new-onset type 2 diabetes. Diabetol Metab Syndr. 2020; 12: 65.
- Romere C, Duerrschmid C, Bournat J, et al. Asprosin, a Fasting-Induced Glucogenic Protein Hormone. Cell. 2016; 165(3): 566–579.
- Long W, Xie X, Du C, et al. Decreased Circulating Levels of Asprosin in Obese Children. Horm Res Paediatr. 2019; 91(4): 271–277.
- Li X, Liao M, Shen R, et al. Plasma Asprosin Levels Are Associated with Glucose Metabolism, Lipid, and Sex Hormone Profiles in Females with Metabolic-Related Diseases. Mediators Inflamm. 2018; 2018: 7375294.
- Wang Y, Qu H, Xiong X, et al. Plasma Asprosin Concentrations Are Increased in Individuals with Glucose Dysregulation and Correlated with Insulin Resistance and First-Phase Insulin Secretion. Mediators Inflamm. 2018; 2018: 9471583.
- Sünnetçi Silistre E, Hatipoğl HU. Increased serum circulating asprosin levels in children with obesity. Pediatr Int. 2020; 62(4): 467–476.
- Liu LJ, Kang YR, Xiao YF. Increased asprosin is associated with non-alcoholic fatty liver disease in children with obesity. World J Pediatr. 2021; 17(4): 394–399.
- Boström P, Wu J, Jedrychowski MP, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012; 481(7382): 463–468.
- Roca-Rivada A, Castelao C, Senin LL, et al. FNDC5/irisin is not only a myokine but also an adipokine. PLoS One. 2013; 8(4): e60563.
- Xiong XQ, Chen D, Sun HJ, et al. FNDC5 overexpression and irisin ameliorate glucose/lipid metabolic derangements and enhance lipolysis in obesity. Biochim Biophys Acta. 2015; 1852(9): 1867–1875.
- Elizondo-Montemayor L, Gonzalez-Gil AM, Tamez-Rivera O, et al. Association between Irisin, hs-CRP, and Metabolic Status in Children and Adolescents with Type 2 Diabetes Mellitus. Mediators Inflamm. 2019; 2019: 6737318.
- AlKhairi I, Cherian P, Abu-Farha M, et al. Increased Expression of Meteorin-Like Hormone in Type 2 Diabetes and Obesity and Its Association with Irisin. Cells. 2019; 8(10).
- Rana KS, Pararasa C, Afzal I, et al. Plasma irisin is elevated in type 2 diabetes and is associated with increased E-selectin levels. Cardiovasc Diabetol. 2017; 16(1): 147.
- Liu JJ, Wong MDS, Toy WC, et al. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications. 2013; 27(4): 365–369.
- Du XL, Jiang WX, Lv ZT. Lower Circulating Irisin Level in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis. Horm Metab Res. 2016; 48(10): 644–652.
- Zhang R, Fu T, Zhao X, et al. Association of Circulating Irisin Levels with Adiposity and Glucose Metabolic Profiles in a Middle-Aged Chinese Population: A Cross-Sectional Study. Diabetes Metab Syndr Obes. 2020; 13: 4105–4112.
- Tang L, Tong Y, Zhang F, et al. The association of circulating irisin with metabolic risk factors in Chinese adults: a cross-sectional community-based study. BMC Endocr Disord. 2019; 19(1): 147.
- Jia J, Yu F, Wei WP, et al. Relationship between circulating irisin levels and overweight/obesity: A meta-analysis. World J Clin Cases. 2019; 7(12): 1444–1455.
- Yilmaz H, Cakmak M, Darcin T, et al. Circulating irisin levels reflect visceral adiposity in non-diabetic patients undergoing hemodialysis. Ren Fail. 2016; 38(6): 914–919.
- Chinese Diabetes Society. [2020 Guideline for the prevention and treatment of type 2 diabetes mellitus in China]. Chin J Diabetes Mellitus. 2021; 13: 315–409.
- American Diabetes Association. 2. Classification and Diagnosis of Diabetes: . Diabetes Care. 2020; 43(Suppl 1): S14–S31.
- Ida M, Hirata M, Odori S, et al. Early changes of abdominal adiposity detected with weekly dual bioelectrical impedance analysis during calorie restriction. Obesity (Silver Spring). 2013; 21(9): E350–E353.
- Marín-Echeverri C, Aristizábal JC, Gallego-Lopera N, et al. Cardiometabolic risk factors in preschool children with abdominal obesity from Medellín, Colombia. J Pediatr Endocrinol Metab. 2018; 31(11): 1179–1189.
- Pausova Z. Visceral Fat and Hypertension: Sex Differences. In: Watson RR. ed. Nutrition in the Prevention and Treatment of Abdominal Obesity. Academic Press, Washington DC 2014: 99–111.
- Al-Daghri NM, Alkharfy KM, Rahman S, et al. Irisin as a predictor of glucose metabolism in children: sexually dimorphic effects. Eur J Clin Invest. 2014; 44(2): 119–124.
- Yoon JH, Lee HL, Kim DW, et al. Is obesity a risk factor for advanced colon polyps in males? Hepatogastroenterology. 2011; 58(109): 1159–1162.
- Kissebah A. Intra-abdominal fat: is it a major factor in developing diabetes and coronary artery disease? Diab Res Clin Pract. 1996; 30: S25–S30.
- Wang XJ, Hu TX, Ruan Y, et al. [Relationship between serum Irisin and abdominal visceral fat area in patients with newly diagnosed type 2 diabetes mellitus]. Chin J Diabetes Mellitus. 202; 29: 488–491.
- Ozcan S, Ulker N, Bulmus O, et al. The modulatory effects of irisin on asprosin, leptin, glucose levels and lipid profile in healthy and obese male and female rats. Arch Physiol Biochem. 2022; 128(3): 724–731.
- Hekim MG, Kelestemur MM, Bulmus FG, et al. Asprosin, a novel glucogenic adipokine: a potential therapeutic implication in diabetes mellitus. Arch Physiol Biochem. 2021 [Epub ahead of print]: 1–7.
- Wiecek M, Szymura J, Maciejczyk M, et al. Acute Anaerobic Exercise Affects the Secretion of Asprosin, Irisin, and Other Cytokines - A Comparison Between Sexes. Front Physiol. 2018; 9: 1782.
